Agile Therapeutics (NASDAQ:AGRX – Get Rating) is set to issue its quarterly earnings data after the market closes on Thursday, August 11th. Parties that are interested in registering for the company’s conference call can do so using this link.
Agile Therapeutics (NASDAQ:AGRX – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) earnings per share for the quarter. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. The company had revenue of $1.76 million for the quarter. On average, analysts expect Agile Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Agile Therapeutics Trading Up 6.4 %
Shares of AGRX stock opened at $0.57 on Thursday. The company’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $6.81. Agile Therapeutics has a 52 week low of $0.49 and a 52 week high of $50.40. The company has a market cap of $2.57 million, a PE ratio of -0.02 and a beta of 1.22.
Institutional Investors Weigh In On Agile Therapeutics
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. Maxim Group raised shares of Agile Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 26th. StockNews.com assumed coverage on shares of Agile Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
- Get a free copy of the StockNews.com research report on Agile Therapeutics (AGRX)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.